Company intelligence / Profile preview

VIBRAGENE

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Vibragene is a clinical-stage biotechnology company focused on developing innovative gene therapies for sensory disorders, particularly genetic hearing loss. The company utilizes its proprietary adeno-associated virus (AAV) platform to deliver functional genes to the inner ear, aiming to restore hearing in patients with sensorineural deafness. Its lead candidate, VG-001, is designed to treat OTOF-related hearing loss and has progressed into clinical trials. Vibragene is headquartered in Suzhou, China, and maintains strong ties to academic research institutions to drive its pipeline of transformative treatments. The company is supported by a group of prominent life science venture capital investors.

Therapeutic areas: NeurologyRare Diseases
Modalities: Gene therapyAdeno-associated virus vector
Industry: Biotech

Beyond the preview

Go deeper on VIBRAGENE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIBRAGENE.

Explore the full profile